$MASI
MASIMO CORP Stock $masi

$masi Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000093755622000090 Filed on May 03, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q2
Revenue	$304.2M	$327.6M	$299.0M
YoY Change	1.74%	11.01%	-0.63%
Cost Of Revenue	$99.48M	$112.7M	$102.2M
YoY Change	-2.63%	4.24%	-6.58%
Gross Profit	$204.8M	$214.9M	$196.9M
YoY Change	4.01%	14.98%	2.76%
Gross Profit Margin	67.3%	65.6%	65.84%
Selling, General & Admin	$108.9M	$104.1M	$96.70M
YoY Change	12.62%	15.29%	-1.79%
% of Gross Profit	53.18%	48.45%	49.12%
Research & Development	$36.12M	$33.37M	$34.51M
YoY Change	4.66%	5.28%	11.77%
% of Gross Profit	17.64%	15.53%	17.53%
Depreciation & Amortization	$9.134M	$9.171M	$8.493M
YoY Change	7.55%	13.22%	60.25%
% of Gross Profit	4.46%	4.27%	4.31%
Operating Expenses	$145.0M	$137.5M	$131.2M
YoY Change	10.52%	12.6%	1.43%
Operating Profit	$59.75M	$77.41M	$65.66M
YoY Change	-9.01%	19.46%	5.54%
Interest Expense	$102.0K	-$547.0K	$84.00K
YoY Change	21.43%	-132.18%	1.2%
% of Operating Profit	0.17%	-0.71%	0.13%
Other Income/Expense, Net	-$608.0K	-$160.0K	-$737.0K
YoY Change	-17.5%	-260.0%	-152.46%
Pretax Income	$59.14M	$76.70M	$64.93M
YoY Change	-8.92%	15.0%	2.05%
Income Tax	$12.54M	$8.446M	$11.54M
% Of Pretax Income	21.21%	11.01%	17.78%
Net Earnings	$46.60M	$68.26M	$53.38M
YoY Change	-12.7%	-3.45%	-4.3%
Net Earnings / Revenue	15.32%	20.84%	17.85%
Basic Earnings Per Share	$0.84	$1.23	$0.97
Diluted Earnings Per Share	$0.81	$1.18	$0.92
COMMON SHARES
Basic Shares Outstanding	55.42M shares	55.36M shares	55.20M shares
Diluted Shares Outstanding	57.31M shares		57.90M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$720.1M	$745.3M	$552.0M
YoY Change	30.45%	16.19%	-19.05%
Cash & Equivalents	$720.1M	$745.3M	$552.0M
Short-Term Investments
Other Short-Term Assets	$91.27M	$91.03M	$80.67M
YoY Change	13.14%	-11.12%	5.17%
Inventory	$213.5M	$201.4M	$216.1M
Prepaid Expenses	$35.68M	$30.88M	$31.93M
Receivables	$199.9M	$200.8M	$134.3M
Other Receivables	$43.40M	$43.92M	$36.30M
Total Short-Term Assets	$1.225B	$1.238B	$983.1M
YoY Change	24.58%	12.46%	-10.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$299.5M	$272.8M	$274.6M
YoY Change	9.1%	0.1%	4.42%
Goodwill	$99.33M	$100.3M	$102.1M
YoY Change	-2.71%	-2.78%	29.6%
Intangibles	$72.28M	$72.50M	$72.94M
YoY Change	-0.9%	-1.92%	27.17%
Long-Term Investments	$13.83M	$13.83M	$7.919M
YoY Change	74.67%	72.83%	-0.39%
Other Assets	$54.62M	$48.58M	$45.87M
YoY Change	19.08%	8.82%	24.07%
Total Long-Term Assets	$684.1M	$648.6M	$614.7M
YoY Change	11.28%	6.09%	13.2%
TOTAL ASSETS
Total Short-Term Assets	$1.225B	$1.238B	$983.1M
Total Long-Term Assets	$684.1M	$648.6M	$614.7M
Total Assets	$1.909B	$1.887B	$1.598B
YoY Change	19.46%	10.19%	-2.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$87.45M	$75.63M	$62.88M
YoY Change	39.07%	18.05%	-29.78%
Accrued Expenses	$11.87M	$12.06M	$8.261M
YoY Change	43.63%	77.52%	33.95%
Deferred Revenue		$50.90M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$254.3M	$267.7M	$196.9M
YoY Change	29.18%	14.5%	-13.48%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.902M	$5.783M	$5.545M
YoY Change	6.44%	-91.86%	40.31%
Total Long-Term Liabilities	$5.902M	$5.783M	$5.545M
YoY Change	6.44%	-91.86%	40.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$254.3M	$267.7M	$196.9M
Total Long-Term Liabilities	$5.902M	$5.783M	$5.545M
Total Liabilities	$326.7M	$336.8M	$269.7M
YoY Change	21.13%	10.45%	-7.35%
SHAREHOLDERS EQUITY
Retained Earnings	$1.617B	$1.571B	$1.395B
YoY Change	15.98%	17.12%	14.2%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$767.7M	$767.7M	$767.7M
YoY Change	0.0%	20.18%	45.62%
Treasury Stock Shares	16.54M shares	16.54M shares	16.54M shares
Shareholders Equity	$1.582B	$1.550B	$1.328B
YoY Change
Total Liabilities & Shareholders Equity	$1.909B	$1.887B	$1.598B
YoY Change	19.46%	10.19%	-2.31%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q2
OPERATING ACTIVITIES
Net Income	$46.60M	$68.26M	$53.38M
YoY Change	-12.7%	-3.45%	-4.3%
Depreciation, Depletion And Amortization	$9.134M	$9.171M	$8.493M
YoY Change	7.55%	13.22%	60.25%
Cash From Operating Activities	$23.16M	$97.60M	$59.26M
YoY Change	-60.92%	51.32%	-6.97%
INVESTING ACTIVITIES
Capital Expenditures	$20.48M	-$6.064M	$8.903M
YoY Change	130.02%	-57.3%	-150.87%
Acquisitions	$0.00		$0.00
YoY Change
Other Investing Activities	-$850.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$23.79M	-$6.064M	-$10.48M
YoY Change	127.1%	203.2%	-81.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$128.9M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$22.22M	4.262M	-$139.9M
YoY Change	-84.11%	-104.57%	-753.51%
NET CHANGE
Cash From Operating Activities	$23.16M	97.60M	$59.26M
Cash From Investing Activities	-$23.79M	-6.064M	-$10.48M
Cash From Financing Activities	-$22.22M	4.262M	-$139.9M
Net Change In Cash	-$25.36M	95.80M	-$90.79M
YoY Change	-72.07%	-411.04%	-403.64%
FREE CASH FLOW
Cash From Operating Activities	$23.16M	$97.60M	$59.26M
Capital Expenditures	$20.48M	-$6.064M	$8.903M
Free Cash Flow	$2.679M	$103.7M	$50.36M
YoY Change	-94.68%	31.72%	-37.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0000937556
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-04-02
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	dei	Entity File Number EntityFileNumber	001-33642
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	MASIMO CORP
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0368882
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	52 Discovery
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine,
CY2022Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92618
CY2022Q2	dei	City Area Code CityAreaCode	(949)
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	297-7000
CY2022Q2	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022Q2	dei	Trading Symbol TradingSymbol	MASI
CY2022Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55504374	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	720108000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	745250000	USD
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2528000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2182000	USD
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	199876000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	200765000	USD
CY2022Q2	us-gaap	Inventory Net InventoryNet	213485000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	201370000	USD
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	91273000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	91027000	USD
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1224742000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1238412000	USD
CY2022Q2	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73922000	USD
CY2022Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73688000	USD
CY2022Q2	us-gaap	Deferred Costs DeferredCosts	33033000	USD
CY2022Q1	us-gaap	Deferred Costs DeferredCosts	28093000	USD
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	299544000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272793000	USD
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72278000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	72502000	USD
CY2022Q2	us-gaap	Goodwill Goodwill	99328000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	100334000	USD
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	51328000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	52607000	USD
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54621000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48581000	USD
CY2022Q2	us-gaap	Assets Assets	1908796000	USD
CY2022Q1	us-gaap	Assets Assets	1887010000	USD
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	87453000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	75627000	USD
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49930000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	70835000	USD
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	48735000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50877000	USD
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	68193000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70397000	USD
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	254311000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	267736000	USD
CY2022Q2	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	72347000	USD
CY2022Q1	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	69029000	USD
CY2022Q2	us-gaap	Liabilities Liabilities	326658000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	336765000	USD
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2022Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55504000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55335000	shares
CY2022Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	56000	USD
CY2022Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	55000	USD
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	16539000	shares
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	16539000	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	767655000	USD
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	767655000	USD
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	740735000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	752513000	USD
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-8455000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-5530000	USD
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1617457000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1570862000	USD
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1582138000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1550245000	USD
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1908796000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1887010000	USD
CY2022Q2	us-gaap	Revenues Revenues	304241000	USD
CY2021Q2	us-gaap	Revenues Revenues	299043000	USD
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	99477000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	102168000	USD
CY2022Q2	us-gaap	Gross Profit GrossProfit	204764000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	196875000	USD
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	108900000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96700000	USD
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36119000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34511000	USD
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	145019000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	131211000	USD
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	59745000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	65664000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12708000	USD
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	128917000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	53383000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2884000	USD
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-608000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-737000	USD
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	59137000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	64927000	USD
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12542000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11544000	USD
CY2022Q2	us-gaap	Profit Loss ProfitLoss	46595000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	53383000	USD
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.97
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.81
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55420000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55200000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57310000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57901000	shares
CY2022Q2	us-gaap	Profit Loss ProfitLoss	46595000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	53383000	USD
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2925000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2884000	USD
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43670000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	50499000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1550245000	USD
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2729000	USD
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25375000	USD
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10869000	USD
CY2022Q2	us-gaap	Profit Loss ProfitLoss	46595000	USD
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2925000	USD
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1582138000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1407640000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2886000	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	16691000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1328125000	USD
CY2022Q2	us-gaap	Profit Loss ProfitLoss	46595000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	53383000	USD
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9134000	USD
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8493000	USD
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	10869000	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	12708000	USD
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-215000	USD
CY2021Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	495000	USD
CY2021Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	49000	USD
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-402000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6823000	USD
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12357000	USD
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	915000	USD
CY2022Q2	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1432000	USD
CY2021Q2	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-16326000	USD
CY2022Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-236000	USD
CY2021Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-919000	USD
CY2022Q2	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	14889000	USD
CY2021Q2	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1307000	USD
CY2022Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	50000	USD
CY2021Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	77000	USD
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9179000	USD
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-599000	USD
CY2022Q2	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-20698000	USD
CY2021Q2	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-23343000	USD
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3536000	USD
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5813000	USD
CY2022Q2	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1312000	USD
CY2021Q2	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-303000	USD
CY2022Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1781000	USD
CY2021Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5308000	USD
CY2022Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-64000	USD
CY2021Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	33000	USD
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23158000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	59260000	USD
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20479000	USD
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8903000	USD
CY2022Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2460000	USD
CY2021Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1572000	USD
CY2022Q2	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	850000	USD
CY2021Q2	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23789000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10475000	USD
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3153000	USD
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5756000	USD
CY2022Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25376000	USD
CY2021Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16691000	USD
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	128917000	USD
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-22223000	USD
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-139852000	USD
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2505000	USD
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	279000	USD
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25359000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90788000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	748378000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	645004000	USD
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	723019000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	554216000	USD
CY2022Q2	us-gaap	Nature Of Operations NatureOfOperations	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Company </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive monitoring technologies and hospital automation solutions. The Company’s mission is to improve patient outcomes and reduce the cost of patient care. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, long-term care facilities, physician offices, veterinarians and consumers through its direct sales force, distributors and original equipment manufacturers (OEM) partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invented Masimo Signal Extraction Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which provides the capabilities of Measure-through Motion and Low Perfusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pulse oximetry to address the primary limitations of conventional pulse oximetry. Over the years, the Company’s product offerings have expanded significantly to also include rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pulse CO-Oximetry, with its ability to monitor carboxyhemoglobin (SpCO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), methemoglobin (SpMet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), total hemoglobin concentration (SpHb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), fractional arterial oxygen saturation (SpfO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Oxygen Content (SpOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Pleth Variability Index (PVi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pleth Variability Index (RPVi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), respiration rate from the pleth (RRp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and Oxygen Reserve Index (ORi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); as well as acoustic respiration monitoring (RRa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), SedLine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brain function monitoring, NomoLine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capnography and gas monitoring and O3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regional Oximetry. These technologies are based upon Masimo SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other proprietary algorithms and are incorporated into a variety of product platforms depending on customers’ specifications. The Company’s current technology offerings also include remote patient monitoring, connectivity, and hospital automation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solutions, including Masimo Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Surveillance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo SafetyNet-Open</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Replica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Iris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MyView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UniView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uniview : 60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Masimo Sleep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Centroid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Bridge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company’s technologies are supported by a substantial intellectual property portfolio that the Company has built through internal development and, to a lesser extent, acquisitions and license agreements.</span></div>
CY2022Q2	us-gaap	Fiscal Period FiscalPeriod	<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2022 is a 52 week fiscal year ending December 31, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div>
CY2022Q2	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
CY2022Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div>
CY2022Q2	masi	Numberof Sourcesof Product Revenue NumberofSourcesofProductRevenue	4	segment
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2487000	USD
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2740000	USD
CY2022Q2	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	2229000	USD
CY2021Q2	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	1112000	USD
CY2022Q2	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-2162000	USD
CY2021Q2	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-733000	USD
CY2022Q2	us-gaap	Product Warranty Expense ProductWarrantyExpense	93000	USD
CY2021Q2	us-gaap	Product Warranty Expense ProductWarrantyExpense	406000	USD
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2461000	USD
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2713000	USD
CY2022Q2	us-gaap	Profit Loss ProfitLoss	46595000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	53383000	USD
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55420000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55200000	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.97
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55420000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55200000	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1890000	shares
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2701000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57310000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57901000	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.81
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	90000	USD
CY2021Q2	us-gaap	Interest Paid Net InterestPaidNet	66000	USD
CY2022Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	5802000	USD
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8320000	USD
CY2021Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	1118000	USD
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	2075000	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1763000	USD
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3316000	USD
CY2022Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5683000	USD
CY2021Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1608000	USD
CY2022Q2	us-gaap	Other Significant Noncash Transaction Consideration Given OtherSignificantNoncashTransactionConsiderationGiven	2,300
CY2022Q2	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2021Q2	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	3374000	USD
CY2022Q2	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	270000	USD
CY2021Q2	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	142000	USD
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	720108000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	551992000	USD
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	2911000	USD
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	2224000	USD
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	723019000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	554216000	USD
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	142533000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	128319000	USD
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	16377000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17140000	USD
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	54575000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	55911000	USD
CY2022Q2	us-gaap	Inventory Net InventoryNet	213485000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	201370000	USD
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	35679000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30879000	USD
CY2022Q2	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28633000	USD
CY2022Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28666000	USD
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	13527000	USD
CY2022Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	12847000	USD
CY2022Q2	us-gaap	Prepaid Royalties PrepaidRoyalties	4447000	USD
CY2022Q1	us-gaap	Prepaid Royalties PrepaidRoyalties	2785000	USD
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	2826000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	3041000	USD
CY2022Q2	us-gaap	Prepaid Taxes PrepaidTaxes	1883000	USD
CY2022Q2	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	102555000	USD
CY2022Q1	us-gaap	Prepaid Taxes PrepaidTaxes	7009000	USD
CY2022Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	1239000	USD
CY2022Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2410000	USD
CY2022Q2	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	3039000	USD
CY2022Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	3390000	USD
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	91273000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	91027000	USD
CY2022Q2	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	13000000	USD
CY2021Q2	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	10000000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	102817000	USD
CY2022Q1	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	102609000	USD
CY2022Q2	masi	Salestypelease Allowancefor Credit Loss SalestypeleaseAllowanceforCreditLoss	262000	USD
CY2022Q1	masi	Salestypelease Allowancefor Credit Loss SalestypeleaseAllowanceforCreditLoss	255000	USD
CY2022Q1	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28666000	USD
CY2022Q1	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	102354000	USD
CY2022Q2	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	28633000	USD
CY2022Q2	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73922000	USD
CY2022Q1	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	73688000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	21887000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	926000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	25614000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1224000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	21994000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1153000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears	16096000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1099000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears	9279000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	928000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter	7685000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	2021000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable SalesTypeAndDirectFinancingLeasesLeaseReceivable	102555000	USD
CY2022Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	7351000	USD
CY2022Q2	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount	0	USD
CY2022Q2	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	102555000	USD
CY2022Q2	masi	Deferred Sales Commissions DeferredSalesCommissions	13313000	USD
CY2022Q1	masi	Deferred Sales Commissions DeferredSalesCommissions	11878000	USD
CY2022Q2	masi	Prepaid Discount PrepaidDiscount	11796000	USD
CY2022Q1	masi	Prepaid Discount PrepaidDiscount	8598000	USD
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	6324000	USD
CY2022Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4970000	USD
CY2022Q2	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	1600000	USD
CY2022Q1	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	2647000	USD
CY2022Q2	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	33033000	USD
CY2022Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	28093000	USD
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	463377000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	430294000	USD
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	163833000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	157501000	USD
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	299544000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272793000	USD
CY2022Q2	us-gaap	Depreciation Depreciation	6500000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	6000000	USD
CY2022Q1	us-gaap	Escrow Deposit EscrowDeposit	21000000	CAD
CY2022Q1	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	123000000	CAD
CY2022Q2	us-gaap	Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease	200000	USD
CY2021Q2	us-gaap	Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease	0	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	120042000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	118529000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	47764000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	46027000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72278000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72502000	USD
CY2022Q2	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7894000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	9142000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7471000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6507000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	5610000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	35654000	USD
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72278000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	100334000	USD
CY2022Q2	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1006000	USD
CY2022Q2	us-gaap	Goodwill Goodwill	99328000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36509000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30486000	USD
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8077000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6371000	USD
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30824000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26290000	USD
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	38901000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	32661000	USD
CY2022Q2	masi	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	16500000	USD
CY2022Q1	masi	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	15200000	USD
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6919000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8982000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7707000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5825000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3216000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9383000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	42032000	USD
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3131000	USD
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	38901000	USD
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	2400000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1900000	USD
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	13832000	USD
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36509000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30486000	USD
CY2022Q1	us-gaap	Equity Method Investments EquityMethodInvestments	13830000	USD
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3887000	USD
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3863000	USD
CY2022Q2	us-gaap	Nontrade Receivables Noncurrent NontradeReceivablesNoncurrent	393000	USD
CY2022Q1	us-gaap	Nontrade Receivables Noncurrent NontradeReceivablesNoncurrent	402000	USD
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54621000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48581000	USD
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	32245000	USD
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	35127000	USD
CY2022Q2	masi	Accruedrebatesandallowances Accruedrebatesandallowances	14881000	USD
CY2022Q1	masi	Accruedrebatesandallowances Accruedrebatesandallowances	13628000	USD
CY2022Q2	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	7249000	USD
CY2022Q1	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	7424000	USD
CY2022Q2	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	54375000	USD
CY2022Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	56179000	USD
CY2022Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5640000	USD
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5302000	USD
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	48735000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50877000	USD
CY2022Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	8298000	USD
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	32245000	USD
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	35127000	USD
CY2022Q2	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	5416000	USD
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1208900000	USD
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	337400000	USD
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	13245000	USD
CY2022Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	16302000	USD
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	13238000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	11996000	USD
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11865000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12061000	USD
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8077000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6371000	USD
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	7846000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	7136000	USD
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3218000	USD
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5618000	USD
CY2022Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2461000	USD
CY2022Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2487000	USD
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	2112000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1989000	USD
CY2022Q2	masi	Accrued Donations Current AccruedDonationsCurrent	1607000	USD
CY2022Q1	masi	Accrued Donations Current AccruedDonationsCurrent	1707000	USD
CY2022Q1	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	16980000	USD
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4524000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4730000	USD
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	68193000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70397000	USD
CY2022Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1900000	USD
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1700000	USD
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30824000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26290000	USD
CY2022Q2	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	16980000	USD
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3280000	USD
CY2022Q2	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	15361000	USD
CY2022Q1	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	14864000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5112000	USD
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5902000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5783000	USD
CY2022Q2	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	72347000	USD
CY2022Q1	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	69029000	USD
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1300000	shares
CY2022Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2021Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	547000	shares
CY2022Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
CY2021Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	235.88
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	128917000	USD
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10900000	USD
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	12700000	USD
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10300000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4000000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2971000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	81.38
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	115000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	157.53
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	152.44
CY2022Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	53000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	51.30
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3018000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	84.50
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	293000	USD
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	217000	USD
CY2022Q2	us-gaap	Interest Expense InterestExpense	102000	USD
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2271000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	62.83
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	three years
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.010
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.009
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.312
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.389
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.309
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.347
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	51.87
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	75.82
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	221300000	USD
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	206400000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	84000	USD
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-799000	USD
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-870000	USD
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-608000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-737000	USD
CY2022Q2	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	1700000	USD
CY2021Q2	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	4300000	USD
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22200000	USD
CY2022Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	20200000	USD
CY2022Q2	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	USD
CY2021Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	900000	USD
CY2022Q2	masi	Severance Plan Participation Agreements SeverancePlanParticipationAgreements	4	Agreement
CY2022Q2	masi	Supplemental Unemployment Benefits Severance Benefits Required Noticeof Resignation SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation	P6M
CY2022Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	157000000	USD
CY2022Q2	us-gaap	Other Commitment OtherCommitment	3600000	USD
CY2022Q2	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1025000000.000	USD
CY2022Q2	masi	Bank Balances BankBalances	720100000	USD
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	5500000	USD
CY2022Q2	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.135
CY2022Q2	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.082
CY2021Q2	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.137
CY2021Q2	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.108
CY2022Q2	masi	Concentration Risk Ar Customer ConcentrationRiskARCustomer	1	Customer
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	304241000	USD
CY2022Q2	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	299043000	USD
CY2021Q2	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	301144000	USD
CY2022Q2	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000
CY2022Q1	us-gaap	Noncurrent Assets NoncurrentAssets	275440000	USD
CY2022Q1	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000

Files In Submission

Name	View Source	Status
0000937556-22-000090-index-headers.html	Edgar Link	pending
0000937556-22-000090-index.html	Edgar Link	pending
0000937556-22-000090.txt	Edgar Link	pending
0000937556-22-000090-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
masi-20220402.htm	Edgar Link	pending
masi-20220402.xsd	Edgar Link	pending
masi-20220402x10qex311.htm	Edgar Link	pending
masi-20220402x10qex312.htm	Edgar Link	pending
masi-20220402x10qex321.htm	Edgar Link	pending
masi-20220402xex101.htm	Edgar Link	pending
masi-20220402xex102.htm	Edgar Link	pending
masi-20220402xex211.htm	Edgar Link	pending
masi-20220402_cal.xml	Edgar Link	unprocessable
masi-20220402_def.xml	Edgar Link	unprocessable
masi-20220402_g1.jpg	Edgar Link	pending
masi-20220402_htm.xml	Edgar Link	completed
masi-20220402_lab.xml	Edgar Link	unprocessable
masi-20220402_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MASI
MASIMO CORP Stock $masi

2022 Q2 Form 10-Q Financial Statement

#000093755622000090 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI MASIMO CORP Stock $masi

2022 Q2 Form 10-Q Financial Statement

#000093755622000090 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI
MASIMO CORP Stock $masi